(European Neurology 1984) reported symptom relief in 97% of opioid withdrawal patients and in 87% of alcohol withdrawal patients
A research peptide might be 95% pure, which is perfectly acceptable for laboratory experiments but potentially concerning for human injection
Insulin-like growth factor 1 and growth hormone in chronic liver disease
Key supporting research from 2024-2025 includes a July 2024 paper in Inflammopharmacology (PMID: 38980576) linking BPC-157 to stress response mechanisms, a January 2025 HSS Journal systematic review on neuromuscular applications (PMID: 40756949), and a 2025 Journal of Neuropsychiatry and Clinical Neurosciences perspectives paper positioning BPC-157 as an emerging therapeutic for CNS disorders
Ingredients Purified water, ethylhexyl palmitate, squalane, cetyl alcohol, dimethyl MEA, algae extract, pullulan, stearic acid, glycerol stearate, PEG-100 stearate, Copper Tripeptide-1 (GHK-Cu), phenoxyethanol, PPG 2 myristyl ether propionate, C10-30 cholesterol/lanosterol esters, polysorbate 80, allantoin, aloe barbadensis (aloe vera) gel, glycine, leucine, tocophersolan (Vitamin E), mixed (alpha, beta, gamma, delta) tocotrienols, mixed (alpha, beta, gamma, delta) tocopherols, ubiquinone (CoQ-10), and xanthophyll (lutein)
